Arrhythmia & EP Perspective

• ECG Challenge: Is Heart Disease Causing His Irregular Pulse? During a routine cardiology visit, a 64-year-old man with a history of coronary artery disease has an irregular pulse. What does the ECG show?
  Medscape Cardiology, December 22, 2023
• Mandrola's Top 10 Cardiology Stories of 2023 Obesity drugs, factor XI inhibitors, and procedures such as TAVR, PCI, and TEER are among the top stories of 2023, according to cardiologist John Mandrola, MD.
  theheart.org on Medscape, December 20, 2023
• Sodium Bicarbonate Use in the Emergency Department Two recent reviews may change how you use bicarb in the ED.
  Medscape Emergency Medicine, December 20, 2023
• Dec 15 2023 This Week in Cardiology   FDA approves PFA, breakthrough in PAH, residual leaks after percutaneous LAAO, OAC in low-intermediate risk people are the topics John Mandrola, MD, discusses in this week’s podcast.
  theheart.org on Medscape, December 15, 2023
• The Top Cardiology Trials of 2023   For this year's review, Bob Harrington and Mike Gibson revisit the major cardiology conferences -- from ACC in New Orleans to AHA in Philly.
  theheart.org on Medscape, December 15, 2023
• Dec 08 2023 This Week in Cardiology   Three aspects of the recent AF guideline documents and a possible new treatment of POTS are the topics John Mandrola, MD, discusses in this week's podcast.
  theheart.org on Medscape, December 08, 2023
• Return to Play in Athletes With Acute Myocarditis An expert analysis of the recommended protocol.
  ACC.org, December 06, 2023
• Dec 01 2023 This Week in Cardiology   More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
  theheart.org on Medscape, December 01, 2023
• Fall Updates in Dementia, PD, and Stroke   Christoph Diener discusses interesting neurology studies published in October, spanning hearing loss and cognitive impairment, Parkinson's disease, and stroke.
  Medscape Neurology, November 22, 2023
• To Anticoagulate or Not in Subclinical AF   John Mandrola and ARTESiA investigator Jeff Healey discuss the results and how they compare with the NOAH-AFNET-6 data on the use of DOACs in patients with short-duration AF.
  theheart.org on Medscape, November 20, 2023
• Diagnosing Cardiac Amyloidosis: 5 Things to Know Dr Taylor Lebeis highlights the key aspects of a diagnostic workup for cardiac amyloidosis.
  American College of Cardiology & Medscape , November 20, 2023
• ECG Challenge: Heart Racing and Cellulitis A patient with diabetes is admitted for cellulitis, and his heart is racing. What's going on?
  Medscape Cardiology, November 20, 2023
• Nov 17 2023 This Week in Cardiology   An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week’s podcast.
  theheart.org on Medscape, November 17, 2023
• AHA 2023 ORBITA-2 Saves Interventional Cardiology, Questions Guidance The second sham-controlled trial of PCI in stable CAD brings relief to the field but challenges our understanding of angina and raises the bar for trials in other specialties, says John Mandrola, MD.
  theheart.org on Medscape, November 13, 2023
• Maternal Perinatal Mortality: A Pediatric Issue Dr Barbara Howard "recently become aware of new data that changes my ideas about what we pediatricians need to be doing as part of our care for children and their families."
  MDedge, November 13, 2023
• Nov 10 2023 This Week in Cardiology   Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
  theheart.org on Medscape, November 10, 2023
• What Not to Prescribe to Older Adults and What to Use Instead   What's in? What's out? In the latest list of potentially inappropriate drugs, the Beers guidance emphasizes clinical judgment.
  Medscape Family Medicine, November 08, 2023
• AHA 2023 Mandrola's Top Trials to Look for at AHA 2023 Semaglutide’s cardiovascular benefit in SELECT, another sham-PCI trial from the ORBITA investigators, and ARTESiA, which examines anticoagulation in subclinical atrial fibrillation, are the top AHA late-breakers for John Mandrola, MD.
  theheart.org on Medscape, November 07, 2023
• AHA 2023 Read clinically focused news coverage of key developments from AHA 2023
  theheart.org on Medscape, November 06, 2023
• AANEM 2023 Read clinically focused news coverage of key developments from AANEM 2023
  Medscape Neurology, November 06, 2023